1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Industry Analysis in European Union, August 2019

Healthcare Industry Analysis in European Union, August 2019

1-30 of about 400 reports

Elafibranor

Elafibranor

  • € 8770
  • Industry report
  • July 2019

Elafibranor (Genfit) is an oral peroxisome proliferator-activated receptor (PPAR) alpha-delta dual agonist. The medication activates PPAR-alpha and PPAR-delta, which control gene expression. Stimulating ...

  • Industries : Healthcare
  • Countries : United States, European Union
Aramchol

Aramchol

  • € 8770
  • Industry report
  • July 2019

Aramchol (arachidyl amido cholanoic acid; Galmed) is a conjugate of cholic acid and arachidic acid, and belongs to the synthetic fatty acid bile acid conjugates (FABACs) family. Aramchol inhibits the live ...

  • Industries : Healthcare
  • Countries : United States, European Union
Cenicriviroc

Cenicriviroc

  • € 8770
  • Industry report
  • July 2019

Cenicriviroc (Allergan/Takeda) is a potent immunomodulator that blocks the chemokine receptors-2/5 (CCR-2/5). CCR-2/5 have been linked to the inflammatory and fibrogenic pathways in non-alcoholic steatohepatitis ...

  • Industries : Healthcare
  • Countries : United States, European Union
Juluca

Juluca

  • € 8770
  • Industry report
  • June 2019

Juluca ([dolutegravir + rilpivirine]; ViiV Healthcare/Johnson and Johnson) is a single-tablet regimen approved in the US for the treatment of patients infected with HIV-1 who have achieved viral supp ...

  • Industries : Therapy
  • Countries : United States, European Union
Complera

Complera

  • € 8770
  • Industry report
  • June 2019

Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson and Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Atripla

Atripla

  • € 8770
  • Industry report
  • June 2019

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Genvoya

Genvoya

  • € 8770
  • Industry report
  • June 2019

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Stribild

Stribild

  • € 8770
  • Industry report
  • June 2019

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed ...

  • Industries : Therapy
  • Countries : United States, European Union, Japan
Tivicay

Tivicay

  • € 8770
  • Industry report
  • June 2019

Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Isentress

Isentress

  • € 8770
  • Industry report
  • June 2019

Isentress (raltegravir; Merck and Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
leronlimab

leronlimab

  • € 8770
  • Industry report
  • June 2019

Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union
Dovato

Dovato

  • € 8770
  • Industry report
  • June 2019

Dovato ([dolutegravir + lamivudine]; ViiV Healthcare) is a single-tablet regimen approved in the US for the treatment of HIV-1 infection in patients who are treatment-naïve. It is also being developed ...

  • Industries : Therapy
  • Countries : United States, European Union
European Union (EU) Point-of-Care Ultrasound (PoCUS) Device Market

European Union (EU) Point-of-Care Ultrasound (PoCUS) Device Market

  • € 3070
  • Industry report
  • May 2019

European Union (EU) Point-of-Care Ultrasound (PoCUS) Device MarketThe European Union point-of-care ultrasound (PoCUS) device market is predicted to attain a size of $230.9 million by 2024, advancing at ...

  • Industries : Health Services
  • Countries : European Union
Global Market for Arthroscopy Products and Sports Medicine Implants (2019)

Global Market for Arthroscopy Products and Sports Medicine Implants (2019)

  • € 4166
  • Industry report
  • April 2019

This Meddevicetracker report provides an analysis of the market for arthroscopy products (including visualization systems, fluid management equipment, and manual and powered instruments) and sports medicine/soft ...

  • Industries : Diagnostic Imaging
  • Countries : World, United States, European Union
Cymbalta

Cymbalta

  • € 8770
  • Industry report
  • March 2019

Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since ...

  • Industries : Pathology, Chronic Disease, Therapy, Mental Health
  • Countries : United States, Japan, European Union
Abilify/Abilify Maintena, Pharma Intelligence

Abilify/Abilify Maintena, Pharma Intelligence

  • € 8770
  • Industry report
  • March 2019

Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Seroquel/Seroquel XR, Pharma Intelligence

Seroquel/Seroquel XR, Pharma Intelligence

  • € 8770
  • Industry report
  • March 2019

The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Rexulti

Rexulti

  • € 8770
  • Industry report
  • March 2019

Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
CB-839

CB-839

  • € 8770
  • Industry report
  • March 2019

Drug OverviewCancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine ...

  • Industries : Cancer, Therapy, Pathology, Oncology
  • Countries : United States, Japan, European Union
Renal cell cancer (RCC) disease forecast and market analysis to 2038

Renal cell cancer (RCC) disease forecast and market analysis to 2038

  • € 19294
  • Industry report
  • March 2019

DISEASE OVERVIEWRenal cell carcinoma (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Afinitor

Afinitor

  • € 8770
  • Industry report
  • March 2019

Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Lenvima

Lenvima

  • € 8770
  • Industry report
  • March 2019

Lenvima (lenvatinib; Eisai/Novartis/Merck and Co) is an orally available small molecule inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), platelet-derived ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Sutent

Sutent

  • € 8770
  • Industry report
  • March 2019

Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth facto ...

  • Industries : Cancer, Therapy, Pathology
  • Countries : United States, Japan, European Union
Votrient

Votrient

  • € 8770
  • Industry report
  • March 2019

Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Avastin

Avastin

  • € 8770
  • Industry report
  • March 2019

Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Nexavar

Nexavar

  • € 8770
  • Industry report
  • March 2019

Nexavar (sorafenib; Bayer/Amgen)  is a small molecule inhibitor that is currently the only targeted treatment available for first-line hepatocellular carcinoma patients.

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Inlyta

Inlyta

  • € 8770
  • Industry report
  • March 2019

Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1.

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Torisel

Torisel

  • € 8770
  • Industry report
  • March 2019

Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
EMA Issues Guidance On Medical Devices That Are Integral To Pharma Products

EMA Issues Guidance On Medical Devices That Are Integral To Pharma Products

  • € 115
  • Industry report
  • March 2019

With its first issue of guidance for the EU Medical Devices Regulation (MDR), the European Medicines Agency has focused on products that contain an “integral medical device” component, such as pre-filled ...

  • Industries : Medical Device
  • Countries : European Union, Europe
Connected Care in Europe – 3rd Edition

Connected Care in Europe – 3rd Edition

  • € 1500
  • Industry report
  • March 2019

The ageing population and the increasing prevalence of chronic diseases will be two of the greatest challenges in Europe during this century. It is widely believed that connected care solutions can ease ...

  • Industries : E-Healthcare, E-Healthcare
  • Countries : European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on